Robert Morgan
Internal Medicine · West Palm Beach, FLNPI 1265867600
Payments from drug & device makers
Across 269 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$687
- Lilly USA, LLC$557
- Pfizer$493
- Exact Sciences$336
- Sumitomo Pharma America, Inc.$276
- Radius Health, Inc.$248
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,90498%
- Education$902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 48 | $687 |
| Lilly USA, LLC | 36 | $557 |
| Pfizer | 25 | $493 |
| Exact Sciences | 16 | $336 |
| Sumitomo Pharma America, Inc. | 15 | $276 |
| Radius Health, Inc. | 10 | $248 |
| AstraZeneca | 13 | $247 |
| Otsuka America Pharmaceutical, Inc. | 10 | $239 |
| Bayer | 10 | $192 |
| Novo Nordisk | 11 | $183 |
| GSK | 10 | $155 |
| AbbVie | 7 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $110 |
| Astellas Pharma US Inc | 2 | $110 |
| Phathom Pharmaceuticals, Inc. | 5 | $99 |
| Lundbeck LLC | 5 | $94 |
| Johnson & Johnson | 6 | $92 |
| Sanofi Pasteur Inc. | 4 | $91 |
| Cardiovascular Systems Inc. | 1 | $83 |
| Abbott | 3 | $74 |
| Idorsia Pharmaceuticals US Inc | 4 | $66 |
| Seqirus USA Inc | 3 | $65 |
| Sanofi-aventis U.S. LLC | 2 | $53 |
| Hologic Sales And Service, LLC | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Edwards Lifesciences | 1 | $33 |
| Shield Therapeutics Inc | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Boston Scientific | 1 | $20 |
| Medtronic | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Merck | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Novartis | 1 | $12 |
How this compares
$4,994 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 121 | $120,078 |
| OzempicSemaglutide | 92 | $90,162 |
| JardianceEmpagliflozin | 81 | $80,954 |
| MounjaroTirzepatide | 33 | $54,914 |
| XareltoRivaroxaban | 47 | $52,229 |
| ProliaDenosumab | 24 | $42,502 |
| JanuviaSitagliptin Phosphate | 33 | $39,385 |
| RybelsusSemaglutide | 30 | $26,187 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $22,978 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $15,214 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $12,846 |
| MyrbetriqMirabegron | 14 | $11,789 |
| LinzessLinaclotide | 11 | $8,404 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $5,829 |
| Levothyroxine Sodium | 468 | $4,951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $493 | $121,507151 claims |
| Novo NordiskOzempic, Rybelsus | $183 | $116,349122 claims |
| Boehringer IngelheimJardiance | $15 | $80,95481 claims |
| MerckJanuvia, Janumet Xr, Janumet | $14 | $67,44559 claims |
| Lilly USA, LLCMounjaro | $557 | $54,91433 claims |
| Johnson & JohnsonXarelto | $92 | $52,22947 claims |
| AmgenProlia | $687 | $42,50224 claims |
| GSKTrelegy Ellipta | $155 | $22,97818 claims |
| Astellas Pharma US IncMyrbetriq | $110 | $11,78914 claims |
| AbbVieLinzess, Synthroid | $113 | $10,66747 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $4,951468 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in West Palm Beach
- Mira BaronWest Palm Beach$29.6M
- Rafael NunezWest Palm Beach$4.6M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.